557TiP SGNTUC-019: Phase II basket study of tucatinib and trastuzumab in previously treated solid tumors with HER2 alterations

M Reck,A Okines,P.R Pohlmann,E Yu,T Bekaii-Saab,Y Nakamura,B.J Monk,D O'Malley,V Kang,L.N Walker,T Stinchcombe

doi:10.1016/j.annonc.2021.08.1079

557TiP SGNTUC-019: Phase II basket study of tucatinib and trastuzumab in previously treated solid tumors with HER2 alterations

M Reck, A Okines + Show 9 more

Open Access

https://doi.org/10.1016/j.annonc.2021.08.1079

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Sep 1, 2021
License type: publisher-specific-oa

Affiliation: German Center for Lung Research, Royal Marsden Hospital, University of Washington, Mayo Clinic, National Cancer Center Hospital East, Arizona Oncology, James Cancer Hospital, The Ohio State University, Seagen (United States), Duke Medical Center

#Dual Targeting Of HER2 #Tucatinib + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Tucatinib (TUC), a highly selective HER2-directed TKI with minimal EGFR inhibition, is approved in combination with trastuzumab (Tras) and capecitabine for adult patients (pts) with HER2 overexpressed/amplified (HER2+) locally-advanced unresectable or metastatic (LAUM) breast cancer (BC). Dual targeting of HER2 with TUC and Tras showed superior activity to either agent alone in HER2+ and HER2-mutated (HER2-mut) xenograft models. Currently, HER2-directed therapies are approved only in HER2+ BC and gastric cancer.

Full Text